ASP Isotopes Subsidiary Seeks HALEU Supply with European Partner, Deliveries from 2028
ASPI•Quantum Leap Energy, a subsidiary of ASP Isotopes, signed a non-binding MOU with a European nuclear technology company to assess a framework for supplying high assay low enriched uranium (HALEU) containing over 10% U-235. The agreement outlines a technical and economic evaluation for delivering HALEU from QLE’s planned conversion and enrichment facilities starting in 2028, scaling quantities through 2036, and extends through December 2030.
1. MOU Overview
Quantum Leap Energy, a wholly owned subsidiary of ASP Isotopes, entered a non-binding Memorandum of Understanding with a European nuclear technology company to explore a long-term collaboration on HALEU supply. The MOU establishes a framework to assess joint responsibilities and feedstock provisions for advanced nuclear fuel production.
2. Technical and Economic Assessment
Under the terms of the MOU, both parties will conduct a detailed technical and economic evaluation of uranium feedstock supply, QLE’s conversion and enrichment processes, and potential deconversion services. The focus will be on producing HALEU containing over 10% uranium-235 for advanced reactor developers.
3. Timeline and Deliverables
The agreement extends through December 31, 2030, with non-binding estimates for HALEU deliveries beginning in 2028 and scaling through 2036 according to the partner’s reactor development schedule. Early termination is allowed by either party, pending completion of the viability study.
